KPF
BMY.RT

K2 Principal Fund’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

K2 Principal Fund’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-60,300
Closed – – 498
2020
Q4 		$0 Buy
60,300
+10,000
+20% +$21.3K ﹤0.01% 428
2020
Q3 		$113K Hold
50,300
– – 0.02% 227
2020
Q2 		$180K Hold
50,300
– – 0.03% 217
2020
Q1 		$191K Hold
50,300
– – 0.04% 189
2019
Q4 		$151K Buy
+50,300
New +$131K 0.01% 277

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

K2 Principal Fund's BMY.RT Position: Q1 2021 in Review

K2 Principal Fund sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 60,300 shares.

K2 Principal Fund first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $191K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • K2 Principal Fund reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • K2 Principal Fund sold 60,300 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021.
  • K2 Principal Fund first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • K2 Principal Fund's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $191K in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on K2 Principal Fund's 13F filing for Q1 2021, filed 14 May 2021.